Novel thermo-sensitive core-shell nanoparticles for targeted paclitaxel delivery

Nanotechnology. 2009 Feb 11;20(6):065104. doi: 10.1088/0957-4484/20/6/065104. Epub 2009 Jan 14.

Abstract

Novel thermo-sensitive nanoparticles self-assembled from poly(N,N-diethylacrylamide-co-acrylamide)-block-poly(gamma-benzyl L-glutamate) were designed for targeted drug delivery in localized hyperthermia. The lower critical solution temperature (LCST) of nanoparticles was adjusted to a level between physiological body temperature (37 degrees C) and that used in local hyperthermia (about 43 degrees C). The temperature-dependent performances of the core-shell nanoparticles were systemically studied by nuclear magnetic resonance (NMR), circular dichroism (CD), fluorescence spectroscopy, dynamic light scattering (DLS), and atom force microscopy (AFM). The mean diameter of the nanoparticles increased slightly from 110 to 129 nm when paclitaxel (PTX), a poorly water-soluble anti-tumor drug, was encapsulated. A stability study in bovine serum albumin (BSA) solution indicated that the PTX loaded nanoparticles may have a long circulation time under physiological environments as the LCST was above physiological body temperature and the shell remained hydrophilic at 37 degrees C. The PTX release profiles showed thermo-sensitive controlled behavior. The proliferation inhibiting activity of PTX loaded nanoparticles was evaluated against Hela cells in vitro, compared with Taxol (a formulation of paclitaxel dissolved in Cremophor EL and ethanol). The cytotoxicity of PTX loaded nanoparticles increased obviously when hyperthermia was performed. The nanoparticles synthesized here could be an ideal candidate for thermal triggered anti-tumor PTX delivery system.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Dosage Forms*
  • HeLa Cells
  • Humans
  • Nanoparticles*
  • Paclitaxel / pharmacology*
  • Temperature

Substances

  • Antineoplastic Agents
  • Dosage Forms
  • Paclitaxel